Compare GE Aerospace (GE) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Aerospace vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? GE Aerospace trades at $308.79 (market cap $319.19B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: GE Aerospace is far larger — about 328.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and GE Aerospace pays a 0.61% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold GE Aerospace for 111 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GE | MRVI | |
|---|---|---|
Market Cap | $319.19B | $972.90M |
Volume | 4,516,693 | 4,325,710 |
Sector | Industrials | Health |
52-Week High | $381.22 | $9.00 |
52-Week Low | $273.25 | $2.83 |
Typical Hold Time | 111 Days | 0 Days |
Enterprise Value | $329.00B | $1.08B |
Dividend Yield | 0.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Aerospace trades at $308.64, showing modest daily gains of 0.14% amid mixed technical signals. The stock maintains strong fundamentals with three consecutive quarterly earnings beats, robust 48.79% ROE, and improving profit margins reaching 18.98% in 2025. Recent news highlights the company's $12 billion CPP acquisition to strengthen its aerospace supply chain capabilities while maintaining shareholder returns through dividends and buybacks.
Outlook remains positive with analyst consensus at $409.60 price target (32.7% upside) and no sell ratings. Key opportunities include aerospace demand growth and strategic acquisitions, while risks involve high valuation multiples (P/E 36.28) and integration challenges from recent M&A activity. The bearish technical picture suggests potential near-term consolidation before fundamental strengths drive long-term appreciation.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
